We are live on ! Find out more
VRDN icon

Viridian Therapeutics
VRDN

55 hedge funds and large institutions have $460M invested in Viridian Therapeutics in 2021 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 22 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

567% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 3

267% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 6

167% more funds holding in top 10

Funds holding in top 10: 3 → 8 (+5)

106% more capital invested

Capital invested by funds: $223M → $460M (+$236M)

41% more funds holding

Funds holding: 39 → 55 (+16)

20.85% more ownership

Funds ownership: 86.24% → 107.09% (+21%)

Holders
55
Holders Change
+16
Holders Change %
+41.03%
% of All Funds
0.85%
Holding in Top 10
8
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+166.67%
% of All Funds
0.12%
New
20
Increased
22
Reduced
6
Closed
3
Calls
$1.27M
Puts
–
Net Calls
+$1.27M
Net Calls Change
+$346K

Top Buyers

Rank Fund Capital Flow
1
VA
VR Adviser
New York
+$34.2M
2
APM
Avidity Partners Management
Texas
+$23.8M
3
BI
BVF Inc
California
+$20M
4
Citadel Advisors
Citadel Advisors
Florida
+$17.6M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$8.64M

Top Sellers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
-$24.7M
2
ABG
Ally Bridge Group
New York
-$5.59M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.55M
4
MS
Maven Securities
Jersey
-$2.2M
5
CAM
Cormorant Asset Management
Massachusetts
-$793K
Name Holding Trade Value Shares
Change 		Change in
Stake
EP
26
Eversept Partners
New York
$3.85M +$644K +34,589 +22%
BlackRock
27
BlackRock
New York
$3.03M +$1.91M +102,285 +201%
SCM
28
Silverarc Capital Management
Massachusetts
$2.45M +$330K +17,728 +17%
Walleye Capital
29
Walleye Capital
New York
$2.18M +$1.63M +87,674 +390%
PVI
30
Pura Vida Investments
New York
$2.07M +$871K +46,764 +80%
AVLSA
31
Atlas Venture Life Science Advisors
Massachusetts
$1.78M +$1.68M +90,072 New
SCM
32
Soleus Capital Management
Connecticut
$1.78M +$1.68M +90,000 New
Marshall Wace
33
Marshall Wace
United Kingdom
$1.75M +$1.65M +88,405 New
ECM
34
ExodusPoint Capital Management
New York
$1.52M +$1.43M +76,757 New
ECM
35
Endurant Capital Management
California
$1.33M +$1.26M +67,450 New
PAMP
36
Polar Asset Management Partners
Ontario, Canada
$1.18M – – –
Northern Trust
37
Northern Trust
Illinois
$1.17M +$460K +24,677 +71%
DCM
38
Driehaus Capital Management
Illinois
$989K – – –
LP
39
LMR Partners
United Kingdom
$818K +$147K +7,892 +24%
State Street
40
State Street
Massachusetts
$673K +$190K +10,200 +43%
MS
41
Maven Securities
Jersey
$434K -$2.2M -118,049 -84%
6CM
42
683 Capital Management
New York
$428K +$403K +21,628 New
SSA
43
Schonfeld Strategic Advisors
New York
$425K -$419K -22,488 -51%
AI
44
Atom Investors
Texas
$373K +$352K +18,884 New
Qube Research & Technologies (QRT)
45
Qube Research & Technologies (QRT)
United Kingdom
$336K +$317K +17,000 New
Citigroup
46
Citigroup
New York
$294K +$277K +14,884 New
Morgan Stanley
47
Morgan Stanley
New York
$271K +$70.3K +3,773 +38%
JP Morgan Chase
48
JP Morgan Chase
New York
$258K +$243K +13,033 New
PP
49
PDT Partners
New York
$249K +$235K +12,615 New
SCP
50
Sender Company & Partners
New York
$242K +$228K +12,216 New
1
2
3

VRDN Hedge Fund Activity: Q4 2021 in Review

55 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q4 2021, worth a combined $460M — up 106% from $223M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new VRDN positions and 3 closed out — a net gain of 17 holders — while 22 added to existing stakes and 6 trimmed.

The largest buyer was VR Adviser, adding an estimated $34.2M. The largest seller was Logos Global Management, exiting entirely with an estimated $24.7M sold.

  • 55 institutional investors held Viridian Therapeutics (VRDN) as of Q4 2021, up from 39 in Q3 2021.
  • Funds reported $460M of Viridian Therapeutics stock for Q4 2021, up 106% quarter-over-quarter.
  • 20 funds opened new Viridian Therapeutics positions in Q4 2021 and 3 closed out, a net change of +17 holders.
  • The largest Viridian Therapeutics buyer in Q4 2021 was VR Adviser, an estimated $34.2M added.
  • The largest Viridian Therapeutics seller in Q4 2021 was Logos Global Management, an estimated $24.7M sold.

Based on aggregated 13F filings for Q4 2021.